Health Care [ 9/12 ] | Biotechnology [ 38/73 ]
NASDAQ | Common Stock
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer.
Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer.
The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial.
It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015.
Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 25 | -0.37 Decreased by -172.55% | -0.38 Increased by +2.63% |
| Mar 17, 25 | -0.37 Increased by +19.57% | -0.36 Decreased by -2.78% |
| Nov 11, 24 | -0.44 Increased by +13.73% | -0.48 Increased by +8.33% |
| Aug 12, 24 | -0.52 Increased by +42.86% | -0.43 Decreased by -20.93% |
| May 13, 24 | 0.51 Increased by +259.38% | -0.58 Increased by +187.93% |
| Mar 18, 24 | -0.46 Decreased by -360.00% | -0.55 Increased by +16.36% |
| Nov 13, 23 | -0.51 Decreased by -292.31% | -0.58 Increased by +12.07% |
| Aug 14, 23 | -0.91 Decreased by -506.67% | -0.90 Decreased by -1.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -15.44 M Decreased by -11.69% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -15.43 M Decreased by -23.79% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -18.18 M Decreased by -32.71% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -20.13 M Decreased by -50.32% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -13.82 M Increased by +66.29% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 634.00 K Increased by +N/A% | -12.46 M Decreased by -3.00% | Decreased by -1.97 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -13.70 M Increased by +13.87% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -13.39 M Increased by +24.59% | Decreased by N/A% Decreased by N/A% |